Table 6.
Baseline characteristics of propensity score matched cohort
| Tioguanine (n = 64) | LDTA (n = 64) | P value | |
|---|---|---|---|
| Age a , median (IQR) | 39.2 (27.4‐53.5) | 38.8 (26.5‐57.8) | 0.773 |
| Sex—male, N (%) | 26 (40.6) | 22 (34.4) | 0.465 |
| Current smoker, N (%) | 11 (17.2) | 17 (26.6) | 0.200 |
| Disease duration in years Median (IQR) | 5.0 (1.3‐12.1) | 5.5 (1.2‐16.3) | 0.705 |
| Treatment duration, median (IQR) | 95.1 (47.1‐104.4) | 85.1 (35.9‐104.1) | 0.388 |
| Follow‐up duration in weeks, median (IQR) | 104.0 (97.8‐104.4) | 104.0 (96.4‐104.1) | 0.323 |
| Type of disease (Crohn's disease), N (%) | 43 (67.2) | 40 (62.5) | 0.663 |
| Crohn's disease disease location, N (%) | 0.125 | ||
| Ileum | 22 (51.2) | 19 (48.7) | |
| Colon | 6 (14.0) | 12 (30.8) | |
| Ileum and colon | 15 (34.9) | 8 (20.5) | |
| Upper GI involvement, N (%) | 2 (4.7) | 3 (7.7) | 0.565 |
| Ulcerative colitis disease location, N (%) | 0.489 | ||
| Proctitis | 1 (4.8) | 1 (4.2) | |
| Left‐sided | 6 (28.6) | 11 (45.8) | |
| Pancolitis | 14 (66.7) | 12 (50.0) | |
| Unknown | — | — | |
| Disease behaviour, N (%) | 0.320 | ||
| Inflammatory disease | 35 (81.4) | 30 (75.0) | |
| Stricturing disease | 4 (9.3) | 8 (20.0) | |
| Penetrating disease | 4 (9.3) | 2 (5.0) | |
| Unknown | — | — | |
| Peri‐anal disease, N (%) | 4 (9.3) | 3 (7.5) | 0.768 |
| Prior intestinal resections, N (%) | 15 (23.4) | 11 (17.2) | 0.331 |
| Prior peri‐anal interventions, N (%) | 3 (7.0) | 1 (2.5) | 0.341 |
| Prior biological therapy use, N (%) | 13 (20.3) | 9 (14.1) | 0.349 |
| Clinical disease activity, N (%) | 0.588 | ||
| Remission | 10 (15.6) | 15 (23.4) | |
| Mild disease | 36 (56.3) | 36 (56.3) | |
| Moderate disease | 16 (25.0) | 11 (17.2) | |
| Unknown | 2 (3.1) | 2 (3.1) | |
| C‐reactive protein (mg/L), Median (IQR) | 4.0 (0.0‐11.8) | 2.0 (0.3‐6.0) | 0.119 |
| Fecal calprotectin (µg/g), Median (IQR) | 227 (168‐409) | 107 (21‐1100) | 0.201 |
| Concomitant medication, N (%) | 1.000 | ||
| No concomitant medication, N (%) | 52 (81.3) | 52 (81.3) | |
| Corticosteroids, N (%) | 12 (18.8) | 12 (18.8) | |
| Corticosteroids range, N (%) | 20 (6‐25) | 20 (13‐36) | |
Baseline characteristics of propensity score matched cohort of IBD patients treated with tioguanine or low dose thiopurine and allopurinol. Variables included: type of inflammatory bowel disease, disease duration, complicated disease (stricturing or penetrating disease for Crohn's disease, pancolitis for ulcerative colitis), peri‐anal disease at baseline, clinical and biochemical disease activity at baseline, corticosteroids at baseline.
Abbreviations: IQR, interquartile range; LDTA, low‐dose thiopurine and allopurinol; N, number of patients.